Waltham, MA J. Calnan and Associates (JC&A) celebrated the grand opening of a new facility at 880 Winter St., for Lyra Therapeutics, a clinical-stage biotechnology company dedicated to addressing unmet medical needs in chronic rhinosinusitis (CRS). 

JC&A was proud to join Lyra Therapeutics, along with members of the project team including Boston Properties, Perkins + Will, and BR+A Engineers, for this important celebration. This milestone marks a significant step forward in the company’s mission to develop innovative treatments for patients who suffer from CRS. 

The newly inaugurated 52,000 s/f cGMP facility features a 5,000 s/f ISO 7 clean room for manufacturing, along with quality control labs, support labs, and office space. 

“The grand opening of Lyra Therapeutics’ new facility at 880 Winter St. is a testament to the power of collaboration and innovation,” said Chet Braun, partner and project executive at JC&A. “We are honored to have played a role in creating a space that will drive important research and improve patient care.” 

880 Winter St., once a standard office building, now boasts custom suites tailored to the unique needs of leading biotech tenants like Lyra Therapeutics, including Carbon Biosciences, Ensem Therapeutics, Mercy BioAnalytics, and TScan. Amenities include a café, fitness center, and corporate center.